CAI Shibin,PAN Yin,MAO Weibo, et al. Clinicopathological characteristics and therapy of 31 cases of papillary carcinoma of the breast[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2017, 47(10): 771-774.
Abstract：Objective: To investigate the clinical and pathological characteristic, therapy method and prognosis in papillary carcinoma of the breast. Methods: The clinical data of 31 cases of patients with breast papillary carcinoma admitted to Lishui Central Hospital from August 2010 to December 2016 were retrospectively analyzed. All cases were performed hematoxylin-eosin (HE) staining and immunohistochemical staining pathologic examination. And the expression of human epidermal growth factor receptor 2 (HER2) gene amplification was detected by fluorescence in situ hybridization. Results: The morbidity of breast papillary carcinoma accounted for 2.71% of breast cancer at the same period, and in most cases painless bony mass in breast or papilla hemorrhagic discharge was discovered in initial diagnosis. Nine patients were undergone modified radical mastectomy, 18 cases were undergone total mastectomy plus sentinel lymph node biopsy (SLNB), and 1 case was undergone breast-conserving radical operation of mastocarcinoma and SLNB. After the operation, 7 cases received adjuvant chemotherapy, 2 cases received radiotherapy and all patients were undergone endocrine therapy. 25 cases had negative result in axillary lymph nodes. 31 cases expressed estrogen receptor or progesterone receptor and 29 cases had negative result in the expression of HER2. The follow-up time was 6 to 80 months, 1 case showed lumbar vertebra metastases in whole-body bone scanning. Other patients had disease free survival and had good living quality. Conclusion: The treatment and prognosis of breast papillary carcinoma are closely related to the pathological pattern. Intraductal papillary carcinoma, encapsulated papillary carcinoma and solid papillary carcinoma have good prognosis and can be dealt with in accordance with the therapeutic principle of carcinoma in situ.
[1] TAN P H, SCHNITT S J, van de VIJVER M J, et al. Papillary and neuroendocrine breast lesions: the WHO stance[J]. Histopathology, 2015, 66(6): 761-770.
[2] LAKHANI S R, ELLIS I O, SCHNITT S J, et al. WHO classification of tumours of the breast[M]. 4thed. Lyon: IARS Press, 2012: 88-94.
[3] 《乳腺癌HER2检测指南(2014版)》编写组. 乳腺癌HER2检测指南(2014版)[J]. 中华病理学杂志, 2014, 43(4): 262-267.
[4] PAL S K, LAU S K, KRUPER L, et al. Papillary carcinoma of the breast: an overview[J]. Breast Cancer Res Treat, 2010,122(3): 637-645.
[5] RAKHA E A, GANDHI N, CLIMENT F, et al. Encapsulated papillary carcinoma of the breast: an invasive tumor with excellent prognosis[J]. Am J Surg Pathol, 2011, 35(8): 1093-1103.
[6] 倪韵碧, 谢文杰. 乳腺乳头状病变[J]. 中华病理学杂志, 2013, 42(11): 721-726.
[7] ESPOSITO N N, DABBS D J, BHARGAVA R. Are encapsulated papillary carcinomas of the breast in situ or invasive? A basement membrane study of 27 cases[J]. Am J Clin Pathol, 2009, 131(2): 228-242.
[8] 罗华荣, 徐铖, 郑海红, 等. 乳腺实性乳头状癌的临床病理特征[J]. 温州医科大学学报, 2015, 45(5): 364-368.
[9] TAN B Y, THIKE A A, ELLIS I O, et al. Clinicopathologic characteristics of solid papillary carcinoma of the breast[J]. Am J Surg Pathol, 2016, 40(10): 1334-1342.
[10] ZHENG Y Z, HU X, SHAO Z M. Clinicopathological characteristics and survival outcomes in invasive papillary carcinoma of the breast: A SEER population-based study[J]. Sci Rep, 2016, 6: 24037.
